Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA:603567)

SHA:603567 Revenue

Heilongjiang ZBD Pharmaceutical had revenue of 181.56M CNY in the quarter ending March 31, 2026, a decrease of -61.28%. This brings the company's revenue in the last twelve months to 509.95M, down -75.19% year-over-year. In the year 2025, Heilongjiang ZBD Pharmaceutical had annual revenue of 797.34M, down -70.51%.

• Revenue (ttm): 509.95M
• Revenue Growth: -75.19%
• P/S Ratio: 8.82
• Revenue / Employee: 260.05K
• Employees: 1,961
• Market Cap: 4.50B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	797.34M	-1.91B	-70.51%
Dec 31, 2024	2.70B	-434.25M	-13.84%
Dec 31, 2023	3.14B	-1.08B	-25.53%
Dec 31, 2022	4.21B	87.33M	2.12%
Dec 31, 2021	4.13B	723.07M	21.24%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 29, 2026

Data Sources Report a data error